Mark L. McCleland

12.2k total citations · 5 hit papers
54 papers, 5.9k citations indexed

About

Mark L. McCleland is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mark L. McCleland has authored 54 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 21 papers in Molecular Biology and 19 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mark L. McCleland's work include Cancer Immunotherapy and Biomarkers (23 papers), Lung Cancer Treatments and Mutations (15 papers) and Microtubule and mitosis dynamics (10 papers). Mark L. McCleland is often cited by papers focused on Cancer Immunotherapy and Biomarkers (23 papers), Lung Cancer Treatments and Mutations (15 papers) and Microtubule and mitosis dynamics (10 papers). Mark L. McCleland collaborates with scholars based in United States, Japan and France. Mark L. McCleland's co-authors include P. Todd Stukenberg, Daniel J. Burke, Jeffrey Shabanowitz, Donald F. Hunt, Forest M. White, Mark M. Ross, Scott B. Ficarro, Marko J. Kallio, Gary J. Gorbsky and Patrick H. O’Farrell and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Genes & Development.

In The Last Decade

Mark L. McCleland

52 papers receiving 5.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phosphoproteome analysis by mass spectrometry and its application to Saccharomyces cerevisiae

2002 1.4k citations Mark L. McCleland, P. Todd Stukenberg et al. profile →
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

2021 484 citations Stephen V. Liu, Martin Reck et al. Journal of Clinical Oncology profile →
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

2020 405 citations Robert M. Jotte, Federico Cappuzzo et al. Journal of Thoracic Oncology profile →
IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

2021 316 citations Mark A. Socinski, Makoto Nishio et al. Journal of Thoracic Oncology profile →
Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial

2020 290 citations Makoto Nishio, Fabrice Barlési et al. Journal of Thoracic Oncology profile →

Peers

Countries citing papers authored by Mark L. McCleland

Since Specialization

Citations

This map shows the geographic impact of Mark L. McCleland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark L. McCleland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark L. McCleland more than expected).

Fields of papers citing papers by Mark L. McCleland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark L. McCleland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark L. McCleland. The network helps show where Mark L. McCleland may publish in the future.

Co-authorship network of co-authors of Mark L. McCleland

This figure shows the co-authorship network connecting the top 25 collaborators of Mark L. McCleland. A scholar is included among the top collaborators of Mark L. McCleland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark L. McCleland. Mark L. McCleland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Preliminary safety, antitumor activity, and circulating tumor DNA (ctDNA) changes with RMC-9805, an oral, RAS(ON) G12D-selective tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors. 2025 ·Journal of Clinical Oncology ·Alexander I. Spira, Kyriakos P. Papadopoulos, Daewon Kim, Aparna R. Parikh, Minal Barve, John D. Powderly, Alexander Starodub, John H. Strickler, Bob T. Li, Paul E. Oberstein, (unknown), Michelle Yang, Mark L. McCleland, Satwant Lally, Wei Lin, Sophia Sohoni, David S. Hong	8
2	Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133) breakdown → 2021 ·Journal of Clinical Oncology ·Stephen V. Liu, Martin Reck, Aaron S. Mansfield, Tony Mok, Arnaud Scherpereel, Niels Reinmuth, Marina Chiara Garassino, Javier de Castro, Raffaele Califano, Makoto Nishio, Francesco Orlandi, Jorge Alatorre-Alexander, Ticiana Leal, Ying Cheng, Jong Seok Lee, Sivuonthanh Lam, Mark L. McCleland, Yu Deng, See Phan, Leora Horn	484
3	Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC 2021 ·Journal of Thoracic Oncology ·Jacek Jassem, Filippo de Marinis, Giuseppe Giaccone, A. Vergnenègre, Carlos H. Barrios, Masahiro Morise, Enriqueta Felip, Cristina Oprean, Young‐Chul Kim, Zoran Andrić, Simonetta Mocci, Ida Enquist, Kimberly M. Komatsubara, Mark L. McCleland, Hiroshi Kuriki, (unknown), See Phan, David R. Spigel, Roy S. Herbst	114
4	Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non–Small Cell Lung Cancer: Results From the Randomized OAK Trial 2021 ·Clinical Lung Cancer ·Shirish M. Gadgeel, Fred R. Hirsch, Keith M. Kerr, Fabrice Barlési, Keunchil Park, Achim Rittmeyer, Wei Zou, (unknown), Hartmut Koeppen, Sarah Paul, David S. Shames, Jing Yi, Christina Matheny, Marcus Ballinger, Mark L. McCleland, David R. Gandara	13
5	Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial. 2020 ·Journal of Thoracic Oncology ·Makoto Nishio, Fabrice Barlési, Howard West, Simon Ball, Rodolfo Bordoni, Manuel Cobo, Pascale Dubray Longeras, Jerome H. Goldschmidt, Silvia Novello, Francesco Orlandi, Rachel E. Sanborn, Zsuzsanna Szalai, (unknown), Diana Mendus, Lijia Wang, Xiaohui Wen, Mark L. McCleland, Tien Hoang, See Phan, Mark A. Socinski	7
6	375O Final efficacy results from IMpower132: First-line atezolizumab + chemotherapy in patients with stage IV non-squamous NSCLC 2020 ·Annals of Oncology ·MAKI NISHIO, Fabrice Barlési, S. Ball, Rodolfo Bordoni, Manuel Cobo, Pascale Dubray‐Longeras, Jerome H. Goldschmidt, Silvia Novello, F. Orlandi, Rachel E. Sanborn, Zsuzsanna Szalai, (unknown), Diana Mendus, (unknown), Xingqiao Wen, Mark L. McCleland, Tien Hoang, S. Phan, Mark A. Socinski	9
7	Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial breakdown → 2020 ·Journal of Thoracic Oncology ·Makoto Nishio, Fabrice Barlési, Howard West, S. Ball, Rodolfo Bordoni, Manuel Cobo, Pascale Dubray Longeras, Jerome H. Goldschmidt, Silvia Novello, Francesco Orlandi, Rachel E. Sanborn, Zsuzsanna Szalai, (unknown), Diana Mendus, Lijia Wang, Xiaohui Wen, Mark L. McCleland, Tien Hoang, See Phan, Mark A. Socinski	290
8	1265P IMpower150: A post hoc analysis of efficacy outcomes in patients with KRAS, STK11 and KEAP1 mutations 2020 ·Annals of Oncology ·Howard West, Federico Cappuzzo, Martin Reck, Tony Mok, Robert M. Jotte, Makoto Nishio, (unknown), S. Morris, G. Shankar, (unknown), (unknown), Mark L. McCleland, Mark A. Socinski	14
9	Clinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: Results from the randomized OAK study 2017 ·Annals of Oncology ·S. Gadgeel, Marcin Kowanetz, Wenbo Zou, Fred R. Hirsch, Keith M. Kerr, David R. Gandara, Fabrice Barlési, (unknown), Mark L. McCleland, Hartmut Koeppen, M. Ballinger, A. Sandler, Priti S. Hegde, Achim Rittmeyer	13
10	Development of a Potent, Specific CDK8 Kinase Inhibitor Which Phenocopies CDK8/19 Knockout Cells 2016 ·ACS Medicinal Chemistry Letters ·Michael F. T. Koehler, Philippe Bergeron, Elizabeth M. Blackwood, Krista K. Bowman, Kevin Clark, Ron Firestein, James R. Kiefer, K. Maskos, Mark L. McCleland, (unknown), Laurent Salphati, (unknown), Elisabeth V. Schneider, Jian Wu, Maureen H. Beresini	65
11	Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8 2016 ·ACS Medicinal Chemistry Letters ·Philippe Bergeron, Michael F. T. Koehler, Elizabeth M. Blackwood, Krista K. Bowman, Kevin Clark, Ron Firestein, James R. Kiefer, K. Maskos, Mark L. McCleland, (unknown), Sreemathy Ramaswamy, Laurent Salphati, (unknown), Elisabeth V. Schneider, Jian Wu, Maureen H. Beresini	47
12	An Integrated Genomic Screen Identifies LDHB as an Essential Gene for Triple-Negative Breast Cancer 2012 ·Cancer Research ·Mark L. McCleland, Adam S. Adler, Yonglei Shang, Thomas Hunsaker, Tom Truong, David Peterson, Eric Torres, (unknown), Benjamin Haley, Jean-Philippe Stéphan, Marcia Belvin, Georgia Hatzivassiliou, Elizabeth M. Blackwood, Laura Corson, Marie Evangelista, Jiping Zha, Ron Firestein	150
13	CDK8 Maintains Tumor Dedifferentiation and Embryonic Stem Cell Pluripotency 2012 ·Cancer Research ·Adam S. Adler, Mark L. McCleland, Tom Truong, (unknown), Zora Modrušan, (unknown), Merone Roose‐Girma, Elizabeth M. Blackwood, Ron Firestein	80
14	Lactate Dehydrogenase B Is Required for the Growth of KRAS-Dependent Lung Adenocarcinomas 2012 ·Clinical Cancer Research ·Mark L. McCleland, Adam S. Adler, (unknown), Ely Cosino, Leslie Lee, Elizabeth M. Blackwood, Margaret Solon, Janet Tao, Li Li, David S. Shames, Erica L. Jackson, William F. Forrest, Ron Firestein	93
15	Developmental Control of Late Replication and S Phase Length 2010 ·Current Biology ·Antony W. Shermoen, Mark L. McCleland, Patrick H. O’Farrell	90
16	The Vertebrate Ndc80 Complex Contains Spc24 and Spc25 Homologs, which Are Required to Establish and Maintain Kinetochore-Microtubule Attachment 2004 ·Current Biology ·Mark L. McCleland, Marko J. Kallio, Gregory A. Barrett‐Wilt, (unknown), Jeffrey Shabanowitz, Donald F. Hunt, Gary J. Gorbsky, P. Todd Stukenberg	143
17	Purification of the Ndc80 Kinetochore Subcomplex From <I>Xenopus</I> Eggs 2004 ·Humana Press eBooks ·Mark L. McCleland, P. Todd Stukenberg	1
18	The highly conserved Ndc80 complex is required for kinetochore assembly, chromosome congression, and spindle checkpoint activity 2003 ·Genes & Development ·Mark L. McCleland, (unknown), Marko J. Kallio, John R. Daum, Gary J. Gorbsky, Daniel J. Burke, P. Todd Stukenberg	217
19	Inhibition of Aurora B Kinase Blocks Chromosome Segregation, Overrides the Spindle Checkpoint, and Perturbs Microtubule Dynamics in Mitosis 2002 ·Current Biology ·Marko J. Kallio, Mark L. McCleland, P. Todd Stukenberg, Gary J. Gorbsky	264
20	Aurora B Kinase Exists in a Complex with Survivin and INCENP and Its Kinase Activity Is Stimulated by Survivin Binding and Phosphorylation 2002 ·Molecular Biology of the Cell ·(unknown), Weijie Lan, Shannon Powers, Mark L. McCleland, Jian Kuang, P. Todd Stukenberg	257

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact